Public healthThrowing science at anti-vaxxers just makes them more hardline

By Tom Stafford

Since the uptick in outbreaks of measles in the United States, those arguing for the right not to vaccinate their children have come under increasing scrutiny. What drives anti-vaxxers is similar to what drives other groups – climate skeptics, for example – which also hold beliefs at odds with conventional scientific thought: It is a process psychologists have called “biased assimilation” — we all regard new information in the light of what we already believe. Research shows that throwing scientific facts at anti-vaxxers is not likely to change minds because the level of knowledge and expertise of the people providing the facts — government, scientists, or journalists, say — was a poor predictor of how much they were trusted on the issue. Instead, what was critical was how much these experts were perceived to have the public’s interests at heart. Researchers who conducted surveys on the issue of pollution, for example, found that groups of people — such as friends and family — who were perceived to want to act in line with the survey respondents’ best interests were highly trusted, even if their expertise on the issue was judged as poor. Rather than lacking scientific facts, anti-vaxxers lack a trust in the establishments which produce and disseminate science.

• Read more

Cybersecurity researchU Wisconsin, shedding 1960s anti-classified research image, launches cybersecurity center

A new cybersecurity research center being built in partnership with private firms and the University of Wisconsin(UW) system aims to attract high-tech research dollars to the state, but administrators must balance the secrecy required for classified research with the openness which is the foundation of academic science. The state legislature passed a 2014 law allowing UW to accept contract for classified work partly in hopes that the school system will lose the perception of being an anti-classified-research environment, a perception dating back to campus protests against military research in the 1960s.

• Read more

R&DYoung researchers increasingly denied research grants, putting the future of U.S. science at risk

America’s youngest scientists, increasingly losing research dollars, are leaving the academic biomedical workforce, a brain drain that poses grave risks for the future of science, according to an article published this week by Johns Hopkins University president Ronald J. Daniels. For example, the number of principal investigators with a leading National Institutes of Health grant who are 36 years old or younger dropped from 18 percent in 1983 to 3 percent in 2010. Meanwhile, the average age when a scientist with a medical degree gets her first of these grants has risen from just under 38 years old in 1980 to more than 45 in 2013.

• Read more

In the trenchesTransforming planes into flying aircraft carriers

Military air operations typically rely on large, manned, robust aircraft, but such missions put these expensive assets — and their pilots — at risk. While small unmanned aircraft systems (UAS) can reduce or eliminate such risks, they lack the speed, range, and endurance of larger aircraft. These complementary traits suggest potential benefits in a blended approach — one in which larger aircraft would carry, launch, and recover multiple small UAS. A flying carrier would allow the United States to use of drones in areas where the United States has no access to nearby airfields, but recovering a drone in mid-air remains a daunting technical challenge.

• Read more

EbolaNew tool can be used as a universal Ebola drug target

University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in this week’s online edition of Protein Science, they have produced a molecule, known as a peptide mimic, which displays a functionally critical region of the virus that is universally conserved in all known species of Ebola. This new tool can be used as a drug target in the discovery of anti-Ebola agents which are effective against all known strains and likely future strains. The same group of biochemists has previously developed highly potent and broadly acting D-peptide inhibitors of HIV entry, currently in preclinical studies, and is now adapting this approach to Ebola using the mimics developed in this study.

• Read more

DHS R&DR&D at DHS is “inherently fragmented”: GAO

The GAO says that DHS does not know how much it spends on R&D, making it difficult for the sprawling agency to oversee and coordinate those efforts. David Maurer, GAO’s director of Homeland Security and Justice, told a House hearing that R&D at DHS is “inherently fragmented.” The reason is that each of several components of the agency — the Science and Technology Directorate, the Coast Guard, and the Domestic Nuclear Detection Office — are given R&D responsibilities by law. At the same time, other DHS components conduct their own R&D efforts as long as those activities are coordinated through the S&T office, Maurer said.

• Read more

EbolaNIH launching human safety study of Ebola vaccine candidate

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will this week begin initial human testing of an investigational vaccine to prevent Ebola virus disease. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will evaluate the experimental vaccine’s safety and ability to generate an immune system response in healthy adults. The study is the first of several Phase 1 clinical trials that will examine the investigational NIAID/GSK Ebola vaccine and an experimental Ebola vaccine developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corp.

• Read more